Sciwind Biosciences, a Chinese drug research and development company for metabolic diseases, announced on Wednesday that it has raised a nearly RMB200 million (US$29.58 million) series A round of financing led by Beijing-based investment firm Legend Capital. The company’s previous investors, namely Chinese healthcare-focused equity investment firm Shenzhen Shiyu Investment Management Co. and bio-engineering products […]

Chinese NASH-Focused Biotech Firm Sciwind Biosciences Raises $29M Series A Round comes originally from China Money Network. All Rights Reserved.

Visit the original source and full text: China Money Network